Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113.3 USD | +1.23% | +4.43% | +3.62% |
May. 14 | Transcript : Revvity, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM | |
Apr. 30 | TD Cowen Adjusts Price Target on Revvity to $130 From $123 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 56.17 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.62% | 13.81B | B+ | ||
+10.03% | 223B | B | ||
+13.59% | 194B | B- | ||
+20.01% | 141B | B- | ||
+30.83% | 109B | A- | ||
+2.05% | 64.85B | A- | ||
+15.38% | 52.7B | B+ | ||
+3.96% | 51.77B | B+ | ||
+8.37% | 44.12B | A | ||
+3.27% | 36.21B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RVTY Stock
- Ratings Revvity, Inc.